Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method wherein a female pig is vaccinated in order to protect a piglet against Streptococcus suis through the intake of colostrum of the vaccinated female pig.

Abstract: The present invention pertains to a vaccine comprising non live Lawsonia intracellularis antigen and a pharmaceutically acceptable carrier for use in a method to reduce in a pig the negative impact on average daily weight gain (ADWG) associated with subclinical infection with Lawsonia intracellularis, by systemic administration of the vaccine to the pig.

Abstract: The present invention provides new multivalent vaccines for felines. The present invention also provides methods of making and using the multivalent vaccines alone or in combinations with other protective agents.

Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.

Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.

Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.

Abstract: The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 ?g per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.

Abstract: The invention pertains to a method to purify coccidial oocysts having dimensions between Dmin and Dmax from faeces comprising the steps of collecting the faeces containing the coccidial oocysts from host animals, diluting the faeces in an aqueous medium, separating a coarse fraction comprising macroscopic particulate matter from the diluted faeces and collecting an aqueous fraction containing the oocysts, characterised in that the method further comprises sieving the aqueous fraction over a first sieve deck having mesh openings to let the oocysts pass, to obtain an aqueous filtrate comprising the oocysts and a first residue comprising particles larger than the oocysts, and sieving the aqueous filtrate over a second sieve deck having mesh openings to obstruct passing of the oocysts through this sieve deck, to obtain a second residue comprising the purified oocysts and a waist filtrate comprising particles smaller than the oocysts.

Abstract: The present invention relates to methods of treating or preventing arthropod infestations of poultry animals and methods of controlling arthropod infestations in poultry animal's environment by administering an isoxazoline compound of formula (I) via drinking water.

Abstract: The instant invention provides compounds of formula I which are selective JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer.

Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.

Abstract: The present invention provides compounds for use in the treatment of respiratory diseases of animals, especially Bovine or Swine Respiratory disease (BRD and SRD).

Abstract: The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Abstract: An apparatus for injecting a liquid into live animals, comprising a cradle plate (18) having a cradle (24) for accommodating at least a part of an animal, sensors (20-1, 20-2, 20-3) for detecting a force acting upon the cradle plate, an injection mechanism (16) for injecting liquid into the animal, and a control unit (38) for triggering the injection mechanism (16) in response to signals received from the sensors, wherein at least three sensors (20-1-, 20-2, 20-3) are arranged for measuring forces with which the cradle plate (18) is pressed against a base (12) in at least three non-aligned positions, and the control unit (38) is adapted to trigger the injection mechanism (16) when the forces measured by the sensors are distributed according to a predetermined pattern.

Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.

Abstract: The invention includes a system and method for predicting the performance of production animals by analysis of heart and lung sounds to determine likelihoods the animals will develop BRD or other diseases or ailments. Vital signs of animals are recorded during an adrenergic sympathetic “flight or fight” situation. A cardio-pulmonary rate ratio is determined for each animal by dividing a normalized adjusted heart rate value by a normalized adjusted respiratory value. From the ratios calculated for each animal in a group, a ratio range is established. Ratio values at a lower end of the ratio range indicate higher relative respiration rates and poor lung performance due to disease. Ratio values at an upper end of the range may indicate low cardiac output and an inability to tolerate rapid weight gain. Ratio values at either end of the range may indicate compromised cardio-pulmonary function.

Abstract: The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection by M. hyo or PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of an M. hyo antigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/M. hyo combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease by M. hyo and PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.

Abstract: A process to prepare a compound of Formula (I) wherein R3, R4 and R5 are each selected independently from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxyl, and wherein the alkyl, alkenyl, alkynyl, and alkoxyl may be optionally substituted with one or more halogen, alkyl, alkenyl, alkynyl, and alkoxyl.

Abstract: The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Abstract: The present invention relates to equine influenza virus (EIV) isolates that when administered in vaccines to equine provide protection against currently emerging EIV strains in the U.S. The present invention also relates to inactivated EIV isolates. In addition, the present invention also relates to safe and efficacious vaccines that comprise the EIV isolates, as well as to corresponding subunit vaccines. The present invention further relates to methods of administering such safe and efficacious vaccines to equine.